Literature DB >> 30604556

How real are 'real-life studies' in psoriasis, and the uncertain meaning of drug persistence.

I Garcia-Doval1,2, P Dávila-Seijo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30604556     DOI： 10.1111/bjd.17104

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  3 in total

1.  Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.

Authors:  Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf
Journal:  JAAD Int       Date:  2020-12-26

Review 2.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

3.  Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice.

Authors:  Cristina Galache Osuna; Borja Gómez-Vila; Javier Aubán Pariente; Beatriz Vázquez Losada; Celia Gómez de Castro; Sheila Requena López; Álvaro de Dios Velázquez; Laura Palacios García; Lucía Ordoñez Fernández; Santiago Gómez Diez; Francisco Vázquez López; Jorge Santos-Juanes
Journal:  Medicina (Kaunas)       Date:  2020-10-30       Impact factor: 2.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.